PRECISION BIOSCIENCES INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
PRECISION BIOSCIENCES INC (DTIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-12
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-06-30 was $200.00K, a 96.67% decline year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-03-31 was $500.00K, a 92.65% decline year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $0.00.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $700.00K, a 95.48% decline from fiscal 2021.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $15.50M, a 50.49% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | ||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 | $100.00K 10-K · filed 2025-03-26 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | $200.00K derived: sum of 3 quarters · filed 2024-03-27 | $700.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $200.00K derived: sum of 2 quarters · filed 2022-11-08 | $700.00K 10-Q · filed 2022-11-08 | $1.30M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2022-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $700.00K 10-Q · filed 2022-08-08 | $1.30M derived: sum of 3 quarters · filed 2023-03-09 | $3.40M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2022-03-31 | $500.00K 10-Q · filed 2022-05-09 | $1.10M derived: sum of 2 quarters · filed 2023-03-09 | $3.20M derived: sum of 3 quarters · filed 2023-03-09 | $9.20M derived: sum of 4 quarters · filed 2023-03-09 | |
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.70M derived: sum of 2 quarters · filed 2023-03-09 | $8.70M derived: sum of 3 quarters · filed 2023-03-09 | $15.50M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $8.10M derived: sum of 2 quarters · filed 2022-11-08 | $14.90M 10-Q · filed 2022-11-08 | $17.00M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $12.80M 10-Q · filed 2022-08-08 | $14.90M derived: sum of 3 quarters · filed 2022-08-08 | $16.40M derived: sum of 4 quarters · filed 2022-08-08 | |
| 2021-03-31 | $6.80M 10-Q · filed 2022-05-09 | $8.90M derived: sum of 2 quarters · filed 2022-05-09 | $10.40M derived: sum of 3 quarters · filed 2022-05-09 | ||
| 2020-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $3.60M derived: sum of 2 quarters · filed 2022-03-15 | $10.30M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $8.20M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $6.70M 10-Q · filed 2021-08-12 | ||||
| 2019-09-30 | $5.30M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |